Medicine
Zavzpret 10 mg/0.1 mL nasal spray
Zavzpret 10 mg/0.1 mL nasal spray is a prescription medicine containing Zavegepant for nasal use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store ZAVZPRET at controlled room temperature, 20°C to 25°C…
Key facts
- Active ingredient (INN)
- Zavegepant
- Brand
- Zavzpret
- Strength
- 10 mg/0.1 mL
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 6 blister pack
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store ZAVZPRET at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 June 2023
- Identifiers
- RxCUI 2637974, 2637980DailyMed set ID 1191475f-e999-49f4-a805-93ad08596b1b, 9c4a7aec-daef-4961-ba77-92f4b58be780NDC 63539-135, 0069-3500Application NDA216386
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 blister pack in 1 carton / 1 vial, single-dose in 1 blister pack / .1 mL in 1 vial, single-dose | 0069-3500-02 | Pfizer Laboratories | 1 June 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 9 March 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Zavegepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as nasal spray. MedsAcross supplies Zavegepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZavegepantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ZAVZPRET prescribing information (US Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Zavzpret 10 mg/0.1 mL nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.